Compound · clinical trials

Rapcabtagene autoleucel clinical trials

Also listed in trial records as YTB323

Source: ClinicalTrials.gov, U.S. National Library of Medicine — the 7 trials in our Switzerland, Germany, France, Spain, Singapore, Italy, Australia, UK, USA, Brazil, Japan, Israel, Netherlands, Taiwan, Denmark, Austria, Czechia, Mexico, South Korea, Sweden, Poland, Norway, Belgium and Canada registers that name Rapcabtagene autoleucel as an intervention. Synced 8 Nov 2026

7Current trials

0Recruiting now

1Lead sponsor

24Country registers

Maintained by Sreepriya Prasannan

MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist

Compiled from ClinicalTrials.gov registry records · Synced 8 Nov 2026 · Editorial standards

At a glance

Rapcabtagene autoleucel is named as an intervention in 7 current clinical trials in our Switzerland, Germany, France, Spain, Singapore, Italy, Australia, UK, USA, Brazil, Japan, Israel, Netherlands, Taiwan, Denmark, Austria, Czechia, Mexico, South Korea, Sweden, Poland, Norway, Belgium and Canada registers. None are recruiting at the moment. The most common phase is Phase 2. The lead sponsor is Novartis Pharmaceuticals. The most-studied condition is ANCA Associated Vasculitis (AAV).

How Rapcabtagene autoleucel works

All drug targets →

Diseases it has been tested for in clinical trials, by furthest phase

Diffuse sclerodermaPhase 2
Granulomatosis with polyangiitisPhase 2
Idiopathic inflammatory myopathyPhase 2
Lupus nephritisPhase 2
Microscopic polyangiitisPhase 2
Systemic lupus erythematosusPhase 2
B-cell chronic lymphocytic leukemiaPhase 1/2
Sjogren syndromePhase 1/2
Acute lymphoblastic leukemiaPhase 1/2
Diffuse large B-cell lymphomaPhase 1/2

12 diseases in all

Mechanisms and diseases from ChEMBL via the Open Targets Platform (release 26.09), ChEMBL record CHEMBL5095147, CC BY-SA 3.0. The Guide to Pharmacology has no record of this medicine, so its targets rest on ChEMBL alone. Trial phases are not approvals: approved uses are shown from the regulators' own records where we hold them.

Patient leaflets for Rapcabtagene autoleucel

The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.

UK
United Kingdom: Search MHRA Products
Patient information leaflets and SmPCs for UK-licensed products.
US
United States: Search DailyMed
FDA-approved labels, including patient and medication guides.

Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.

Trials by status

Active, closed7100%

Trials by phase

Phase 2457%
Phase 1/2343%

Clinical trials of Rapcabtagene autoleucel

7 trials

Study	Phase	Status	Lead sponsor	Registers
A Study of Rapcabtagene Autoleucel in Active, Refractory Systemic Lupus Erythematosus (SLE) or Lupus Nephritis (LN) Patients (AUTOGRAPH - SLE/LN) NCT06581198 · Lupus Erythematosus, Systemic, Lupus Nephritis	Phase 2	Active, closed	Novartis Pharmaceuticals	UK, USA, Germany, France, Spain, Italy, Netherlands, Sweden, Denmark, Poland, Switzerland, Austria, Czechia, Norway, Brazil, Mexico, Japan, South Korea, Taiwan, Singapore, Australia, Israel
Phase 2 Study Evaluating Rapcabtagene Autoleucel in Participants With Diffuse Cutaneous Systemic Sclerosis NCT06655896 · Scleroderma, Diffuse	Phase 2	Active, closed	Novartis Pharmaceuticals	UK, USA, Germany, France, Spain, Italy, Netherlands, Belgium, Denmark, Switzerland, Austria, Czechia, Brazil, Mexico, Japan, South Korea, Taiwan, Singapore, Australia, Israel
Phase 2 Study of Rapcabtagene Autoleucel in Myositis NCT06665256 · Idiopathic Inflammatory Myopathies	Phase 2	Active, closed	Novartis Pharmaceuticals	UK, USA, Germany, France, Spain, Italy, Netherlands, Switzerland, Brazil, Japan, Taiwan, Singapore, Australia, Israel
Phase 2 Study Evaluating Rapcabtagene Autoleucel in Participants With Severe Active GPA or MPA NCT06868290 · ANCA Associated Vasculitis (AAV)	Phase 2	Active, closed	Novartis Pharmaceuticals	UK, USA, Switzerland, Brazil, Japan, Singapore, Israel
An Open-label Study to Assess the Safety, Efficacy, and Cellular Kinetics of YTB323 in Relapsing Multiple Sclerosis NCT06617793 · ClinicalTrials.gov ↗ · Relapsing Multiple Sclerosis	Phase 1/2	Active, closed	Novartis Pharmaceuticals	Germany, France, Spain, Italy, Switzerland, Australia
Open-label, Multi-center, Phase I/II Study to Assess Safety, Disease Progression and Cellular Kinetics Following YTB323 Administration in Participants With Non-active Progressive Multiple Sclerosis (PMS) NCT06675864 · ClinicalTrials.gov ↗ · Progressive Multiple Sclerosis	Phase 1/2	Active, closed	Novartis Pharmaceuticals	Germany, France, Spain, Italy, Switzerland, Canada, Australia
A Study to Assess Safety, Cellular Kinetics and Exploratory Efficacy of Rapcabtagene Autoleucel in Rheumatoid Arthritis and Sjogren's Disease NCT07048197 · ClinicalTrials.gov ↗ · Rheumatoid Arthritis (RA) and Sjögren's Disease (SjD)	Phase 1/2	Active, closed	Novartis Pharmaceuticals	Germany, France, Spain, Singapore

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.

Conditions studied with Rapcabtagene autoleucel

8 conditions

ANCA Associated Vasculitis (AAV)1Idiopathic Inflammatory Myopathies1Lupus Erythematosus, Systemic1 Lupus Nephritis1Scleroderma, Diffuse1Rheumatoid Arthritis (RA) and Sjögren's Disease (SjD)1Progressive Multiple Sclerosis1Relapsing Multiple Sclerosis1

By country register

Register	Trials	Recruiting
Clinical trials in Switzerland	6	0
Clinical trials in Germany	6	0
Clinical trials in France	6	0
Clinical trials in Spain	6	0
Clinical trials in Singapore	5	0
Clinical trials in Italy	5	0
Clinical trials in Australia	5	0
Clinical trials in UK	4	0
Clinical trials in USA	4	0
Clinical trials in Brazil	4	0
Clinical trials in Japan	4	0
Clinical trials in Israel	4	0
Clinical trials in Netherlands	3	0
Clinical trials in Taiwan	3	0
Clinical trials in Denmark	2	0
Clinical trials in Austria	2	0
Clinical trials in Czechia	2	0
Clinical trials in Mexico	2	0
Clinical trials in South Korea	2	0
Clinical trials in Sweden	1	0
Clinical trials in Poland	1	0
Clinical trials in Norway	1	0
Clinical trials in Belgium	1	0
Clinical trials in Canada	1	0

A trial with sites in more than one country appears in each of those registers.

Related compounds

Questions about Rapcabtagene autoleucel trials

How many clinical trials are testing Rapcabtagene autoleucel?

7 current trials in our Switzerland, Germany, France, Spain, Singapore, Italy, Australia, UK, USA, Brazil, Japan, Israel, Netherlands, Taiwan, Denmark, Austria, Czechia, Mexico, South Korea, Sweden, Poland, Norway, Belgium and Canada registers name Rapcabtagene autoleucel (also registered as YTB323) as a drug or biological intervention, as of the registry sync on 8 November 2026. Completed and withdrawn studies are not counted.

Are Rapcabtagene autoleucel trials recruiting patients?

Not at the moment. None of the 7 trials in our registers is recruiting; they are active but closed to enrolment, not yet open, or enrolling by invitation. Only the study team can confirm whether a patient is eligible.

Who sponsors Rapcabtagene autoleucel clinical trials?

The lead sponsor is Novartis Pharmaceuticals. The number in brackets is how many trials each organisation leads.

Where does this information come from?

Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Rapcabtagene autoleucel works or whether it is effective, and it is not medical advice.

How this page is built

Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Rapcabtagene autoleucel works or whether it is effective. Each trial links to its own record so you can check it yourself.

ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page

This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Rapcabtagene autoleucel (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 8 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.